Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
AJANTA PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AJANTA PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
AJANTA PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,426 | 314 | - | |
Low | Rs | 1,062 | 226 | - | |
Sales per share (Unadj.) | Rs | 297.2 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | 46.7 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | 57.1 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 7.00 | 0 | - | |
Avg Dividend yield | % | 0.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 269.1 | 73.3 | - | |
Shares outstanding (eoy) | m | 125.91 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 4.2 | 2.9 | 144.6% | |
Avg P/E ratio | x | 26.6 | -11.5 | -232.0% | |
P/CF ratio (eoy) | x | 21.8 | -13.9 | -157.3% | |
Price / Book Value ratio | x | 4.6 | 3.7 | 125.4% | |
Dividend payout | % | 15.0 | 0 | - | |
Avg Mkt Cap | Rs m | 156,638 | 45,603 | 343.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 7,851 | 2,862 | 274.3% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 37,426 | 15,761 | 237.5% | |
Other income | Rs m | 986 | 110 | 893.7% | |
Total revenues | Rs m | 38,413 | 15,872 | 242.0% | |
Gross profit | Rs m | 7,833 | -2,731 | -286.8% | |
Depreciation | Rs m | 1,308 | 680 | 192.3% | |
Interest | Rs m | 58 | 427 | 13.7% | |
Profit before tax | Rs m | 7,453 | -3,728 | -199.9% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,573 | 233 | 675.1% | |
Profit after tax | Rs m | 5,880 | -3,971 | -148.1% | |
Gross profit margin | % | 20.9 | -17.3 | -120.8% | |
Effective tax rate | % | 21.1 | -6.2 | -337.7% | |
Net profit margin | % | 15.7 | -25.2 | -62.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 28,252 | 11,544 | 244.7% | |
Current liabilities | Rs m | 11,393 | 6,495 | 175.4% | |
Net working cap to sales | % | 45.0 | 32.0 | 140.6% | |
Current ratio | x | 2.5 | 1.8 | 139.5% | |
Inventory Days | Days | 66 | 111 | 59.4% | |
Debtors Days | Days | 10 | 124 | 8.3% | |
Net fixed assets | Rs m | 18,707 | 6,729 | 278.0% | |
Share capital | Rs m | 253 | 73 | 345.3% | |
Net worth | Rs m | 33,877 | 12,371 | 273.8% | |
Long term debt | Rs m | 13 | 4,347 | 0.3% | |
Total assets | Rs m | 47,047 | 23,369 | 201.3% | |
Interest coverage | x | 128.6 | -7.7 | -1,663.3% | |
Debt to equity ratio | x | 0 | 0.4 | 0.1% | |
Sales to assets ratio | x | 0.8 | 0.7 | 118.0% | |
Return on assets | % | 12.6 | -15.2 | -83.2% | |
Return on equity | % | 17.4 | -32.1 | -54.1% | |
Return on capital | % | 22.2 | -19.8 | -111.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 7,918 | 1,345 | 588.5% | |
From Investments | Rs m | -5,596 | -413 | 1,354.7% | |
From Financial Activity | Rs m | -1,079 | 3,945 | -27.3% | |
Net Cashflow | Rs m | 1,243 | 4,878 | 25.5% |
Compare AJANTA PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare AJANTA PHARMA With: VINEET LABORATORIES SHILPA MEDICARE NATURAL CAPS SUVEN PHARMACEUTICALS AMI ORGANICS
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.